Update information
Minor changes since publication
November 2023: The wording in recommendation 1.1 and section 2 has been updated to include procurement information about natalizumab biosimilars.
March 2014: Implementation section was updated to clarify that natalizumab is recommended as an option for treating highly active relapsing–remitting multiple sclerosis. Additional minor maintenance update also carried out.
March 2012: Minor maintenance.
ISBN: 978-1-4731-5586-2